718 related articles for article (PubMed ID: 26170167)
1. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.
Chen J; Jin R; Zhao J; Liu J; Ying H; Yan H; Zhou S; Liang Y; Huang D; Liang X; Yu H; Lin H; Cai X
Cancer Lett; 2015 Oct; 367(1):1-11. PubMed ID: 26170167
[TBL] [Abstract][Full Text] [Related]
2. Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma.
Mir N; Jayachandran A; Dhungel B; Shrestha R; Steel JC
Curr Cancer Drug Targets; 2017; 17(8):698-706. PubMed ID: 28460616
[TBL] [Abstract][Full Text] [Related]
3. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
5. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
Yoon EL; Yeon JE; Lee HJ; Suh SJ; Lee SJ; Kang SH; Kang K; Yoo YJ; Kim JH; Yim HJ; Byun KS
J Clin Gastroenterol; 2014 Mar; 48(3):e22-9. PubMed ID: 24045282
[TBL] [Abstract][Full Text] [Related]
6. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
[No Abstract] [Full Text] [Related]
8. New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies.
Niu L; Liu L; Yang S; Ren J; Lai PBS; Chen GG
Biochim Biophys Acta Rev Cancer; 2017 Dec; 1868(2):564-570. PubMed ID: 29054475
[TBL] [Abstract][Full Text] [Related]
9. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
10. The role of sorafenib in hepatocellular carcinoma.
Gholam P
Clin Adv Hematol Oncol; 2015 Apr; 13(4):232-4. PubMed ID: 26352581
[No Abstract] [Full Text] [Related]
11. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma.
Deng YR; Liu WB; Lian ZX; Li X; Hou X
Oncotarget; 2016 Jun; 7(25):38292-38305. PubMed ID: 27203677
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib: from literature to clinical practice.
Di Marco V; De Vita F; Koskinas J; Semela D; Toniutto P; Verslype C
Ann Oncol; 2013 Apr; 24 Suppl 2():ii30-7. PubMed ID: 23715941
[TBL] [Abstract][Full Text] [Related]
14. Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma.
Nishida N; Kitano M; Sakurai T; Kudo M
Dig Dis; 2015 Oct; 33(6):771-9. PubMed ID: 26488287
[TBL] [Abstract][Full Text] [Related]
15. Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
Smolle E; Taucher V; Petru E; Haybaeck J
Anticancer Res; 2014 Apr; 34(4):1519-30. PubMed ID: 24692678
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.
Gao JJ; Shi ZY; Xia JF; Inagaki Y; Tang W
World J Gastroenterol; 2015 Nov; 21(42):12059-70. PubMed ID: 26576091
[TBL] [Abstract][Full Text] [Related]
17. Extrahepatic spread of hepatocellular carcinoma.
Cabibbo G; Compilato D; Genco C; Campisi G
Panminerva Med; 2012 Dec; 54(4):313-22. PubMed ID: 23123584
[TBL] [Abstract][Full Text] [Related]
18. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
Jia H; Yang Q; Wang T; Cao Y; Jiang QY; Ma HD; Sun HW; Hou MX; Yang YP; Feng F
Biochim Biophys Acta; 2016 Jul; 1860(7):1417-30. PubMed ID: 27091611
[TBL] [Abstract][Full Text] [Related]
19. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Casadei Gardini A; Faloppi L; De Matteis S; Foschi FG; Silvestris N; Tovoli F; Palmieri V; Marisi G; Brunetti O; Vespasiani-Gentilucci U; Perrone G; Valgiusti M; Granato AM; Ercolani G; Negrini G; Tamburini E; Aprile G; Passardi A; Santini D; Cascinu S; Frassineti GL; Scartozzi M
Eur J Cancer; 2017 Nov; 86():106-114. PubMed ID: 28985579
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy.
Hung MH; Tai WT; Shiau CW; Chen KF
World J Gastroenterol; 2014 Nov; 20(41):15269-74. PubMed ID: 25386075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
